SB216763

Package : 10mg

Technical literature is available at: www.mesgenbio.com. E-mail MesGen Technical Services if you have questions on use of this system: tech@mesgenbio.com

MESGEN INNOVATION BIOTECHNOLOGY

Catalog Number : MG29903

CAS : 280744-09-4

Appearance : Off-white to orange(solid)

Purity ≥98% by HPLC

Molecular weight : 371.22

Molecular formula : $C_{19}H_{12}Cl_2N_2O_2$



Description

A cell-permeable (arylindole) maleimide compound that acts as a potent, selective, ATP-competitive inhibitor of GSK-3 activity (K_i = 9.1 nM for GSK-3α). At 10 μM concentration, does not significantly inhibit a panel of 24 other protein kinases tested. Reported to stimulate glycogen synthesis in Chang human liver cells (EC_{50} = 3.6 μM) and induce transcription of β-catenin-LEF/TCF (lymphoid enhancer factor/T cell factor) regulated reporter gene in HEK293 human embryonic kidney cell lines. Offers protection against polyglutamine-induced death in SK-N-SH and COS-7 cells and attenuates hypoxia-induced apoptosis in VSMC and COS-7 cells. Shown to reduce phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) expression in hepatoma cells. Promotes the survival of CLL lymphocytes via Wnt/β-catenin-mediated transcription activation. Exhibits delayed cardioprotection *in vivo* in a rat model via a KATP (ATP-sensitive potassium channels) and MPTP (mitochondrial permeability transition pore)-dependent mechanism at reperfusion.

A cell-permeable (aryl,indole) maleimide compound that acts as a potent, selective, ATP-competitive inhibitor of GSK-3 activity (K_i = 9.1 nM for GSK-3α). At 10 μM concentration, does not significantly inhibit a panel of 24 other protein kinases tested. Reported to stimulate glycogen synthesis in Chang human liver cells (EC_{50} = 3.6 μM) and induce transcription of β-catenin-LEF/TCF (lymphoid enhancer factor/T cell factor) regulated reporter gene in HEK293 human embryonic kidney cell lines. Offers protection against polyglutamine-induced death in SK-N-SH and COS-7 cells and attenuates hypoxia-induced apoptosis in VSMC and COS-7 cells. Shown to reduce phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) expression in hepatoma cells. Promotes the survival of CLL lymphocytes via Wnt/β-catenin-mediated transcription activation. Exhibits delayed cardioprotection *in vivo* in a rat model via a KATP (ATP-sensitive potassium channels) and MPTP (mitochondrial permeability transition pore)-dependent mechanism at reperfusion.

Solvent & Solubility

DMSO ≥25mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL

Storage condition

-20°C

For Research Use Only. Not For Use In Diagnostic Procedures.

MesGen Biotechnology **Tel : 86-21-56620378 | China (mainland)**
tech@mesgenbio.com | www.mesgenbio.com